SynCore Biotechnology Co Ltd (4192) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SynCore Biotechnology Co Ltd (4192) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-7.18 Million ≈ $-226.11K USD) by net assets (NT$257.97 Million ≈ $8.13 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SynCore Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how SynCore Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 4192 liabilities breakdown for a breakdown of total debt and financial obligations.
SynCore Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SynCore Biotechnology Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sintercom India Limited
NSE:SINTERCOM
|
0.040x |
|
Global SM Tech Limited
KQ:900070
|
0.009x |
|
Giyani Metals Corp
V:EMM
|
-0.058x |
|
Jullundur Motor Agency (Delhi) Limited
NSE:JMA
|
0.051x |
|
NEVADA LITHIUM RESOURCES
F:87K
|
-0.016x |
|
WITTED MEGACORP OYJ EO 1
F:8OS
|
N/A |
|
Galileo Mining Ltd
AU:GAL
|
-0.001x |
|
Advicenne
PA:ALDVI
|
-0.079x |
Annual Cash Flow Conversion Efficiency for SynCore Biotechnology Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of SynCore Biotechnology Co Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SynCore Biotechnology Co Ltd (4192) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$294.69 Million ≈ $9.28 Million |
NT$-49.24 Million ≈ $-1.55 Million |
-0.167x | +27.55% |
| 2023-12-31 | NT$357.14 Million ≈ $11.25 Million |
NT$-82.37 Million ≈ $-2.60 Million |
-0.231x | +72.60% |
| 2022-12-31 | NT$249.01 Million ≈ $7.85 Million |
NT$-209.61 Million ≈ $-6.60 Million |
-0.842x | -62.20% |
| 2021-12-31 | NT$442.92 Million ≈ $13.95 Million |
NT$-229.86 Million ≈ $-7.24 Million |
-0.519x | +8.12% |
| 2020-12-31 | NT$560.58 Million ≈ $17.66 Million |
NT$-316.63 Million ≈ $-9.98 Million |
-0.565x | +17.41% |
| 2019-12-31 | NT$612.03 Million ≈ $19.28 Million |
NT$-418.57 Million ≈ $-13.19 Million |
-0.684x | -77.52% |
| 2018-12-31 | NT$706.70 Million ≈ $22.26 Million |
NT$-272.26 Million ≈ $-8.58 Million |
-0.385x | -37.46% |
| 2017-12-31 | NT$720.61 Million ≈ $22.70 Million |
NT$-201.96 Million ≈ $-6.36 Million |
-0.280x | -38.83% |
| 2016-12-31 | NT$966.36 Million ≈ $30.45 Million |
NT$-195.09 Million ≈ $-6.15 Million |
-0.202x | -9.04% |
| 2015-12-31 | NT$842.81 Million ≈ $26.55 Million |
NT$-156.03 Million ≈ $-4.92 Million |
-0.185x | -- |
About SynCore Biotechnology Co Ltd
SynCore Biotechnology Co.,Ltd, engages in development and sale of food advisory, medicine inspection, and biotechnology service in Taiwan. The company is involved in the development of SB01, an injectable anti-cancer new ingredient (NCE) that is in Phase II clinical trials for the treatment of head and neck cancer; and SB02, an anti-cancer NCE, which is in preclinical research for use in the trea… Read more